✦ LIBER ✦

Mitochondrial therapies for Parkinson's disease

✍ Scribed by Bobby Thomas; M. Flint Beal

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 73 KB
Volume: 25
Category: Article
ISSN: 0885-3185
DOI: 10.1002/mds.22781

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Parkinson's disease (PD) is marked by widespread neurodegeneration in the brain in addition to a selective yet prominent and progressive loss of nigrostriatal dopaminergic neurons. Of the multiple theories suggested in the pathogenesis of PD, mitochondrial dysfunction takes a center stage in both sporadic and familial forms of illness. Deficits in mitochondrial functions due to impaired bioenergetics, aging associated increased generation of reactive oxygen species, damage to mitochondrial DNA, impaired calcium buffering, and alterations in mitochondrial morphology may contribute to improper functioning of the CNS leading to neurodegeneration. These mitochondrial alterations suggest that a potential target worth exploring for neuroprotective therapies are the ones that can preserve mitochondrial functions in PD. Here, we provide a recent update on potential drugs that are known to block mitochondrial dysfunctions in various experimental models and those that are currently under clinical trials for PD. We also review novel mitochondrial survival pathways that provide hope and promise for innovative neuroprotective therapies in the future that can be explored as possible therapeutic intervention for PD pathogenesis. © 2010 Movement Disorder Society

📜 SIMILAR VOLUMES

Parkinson's disease/Parkinson syndromes—

Parkinson's disease/Parkinson syndromes—mitochondrial abnormalities

📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 237 KB

Recently, it was reported that parkinsonlan patients exhibit mitochondrial abnormalhies which might be related to the production of either endogenous or exogenous toxins. We, thus, assessed possible inhibitory effects of dopamine-related compounds on mitochondrial respiration in rat brain. We found

Neuroprotective Therapy for Parkinson's

Neuroprotective Therapy for Parkinson's disease

✍ I.Shoulson and the Parkinson Study Group 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB 👁 1 views

In the context of degenerative disorders of the basal ganglia, neuroprotective therapy refers to interventions that preserve the integrity and function of vulnerable neurons and thereby slow or halt clinical decline. Decoppering therapy for Wilson's disease is the only established neuroprotective th

Milacemide therapy for Parkinson's disea

Milacemide therapy for Parkinson's disease

✍ M. E. Giuffra; V. H. Sethy; T. L. Davis; M. M. Mouradian; Dr. T. N. Chase 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 303 KB

## Abstract The clinical effects of central glutamatergic stimulation by the glycine prodrug milacemide were studied in six patients with Parkinson's disease under double‐blind, placebo‐controlled conditions. When administered as monotherapy at a single oral dose of 1,200 mg, the drug increased ove

Gene therapy for Parkinson's disease

✍ Tomas Bjorklund; Jeffrey H. Kordower 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 133 KB

## Abstract The once fantastic theoretical concept that patients with Parkinson's disease (PD) would receive gene therapy in an attempt to alleviate their symptoms and potentially modify the course of their disease has become a reality. On the basis of positive preclinical data, four different gene

Systematic review of paramedical therapi

Systematic review of paramedical therapies for Parkinson's disease

✍ Katherine H.O. Deane; Caroline Ellis-Hill; Diana Jones; Renata Whurr; Yoav Ben-S 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB

## Abstract We evaluated the efficacy of physiotherapy, occupational therapy, and speech and language therapy in Parkinson's disease by synthesizing six Cochrane systematic reviews. All randomised, controlled trials examining the efficacy of a paramedical therapy versus control intervention and all

Mitochondrial function in Parkinson's di

Mitochondrial function in Parkinson's disease

✍ Fiorenzo Dagani; Jeffrey J. Anderson; Thomas N. Chase 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 236 KB 👁 2 views